The Danish magazine MedWatch has released an article about PentaBase as top story in their newsletter today (12/16/2019). The article is about PentaBase and our newly received Innobooster-funding from Innovationsfonden.
The last two years, MicroSight® MSI test has been of highest priority for PentaBase and the product is soon ready to be released to the market. MicroSight® MSI is the first method to give an objective answer on a patients MSI status from known biomarkers – all this in less than two hours. It is therefore a great honor to have received Innobooster-funding from Innovationsfunden. The Innobooster-funding will be used to make the product fully ready for the market and for further optimization of MicroSight® MSI, which includes expansion of the test for use in more cancers.
To read the article please use the link below.